How do you approach patients with stage III melanoma for adjuvant treatment?

Currently, there are FDA-approved adjuvant systemic therapy for stage III melanoma. These were based on the CheckMate 238 study (adjuvant nivolumab), KEYNOTE-054 (adjuvant pembrolizumab), and COMBI-AD study (adjuvant dabrafenib/trametinib). The KEYNOTE-054 compared adjuvant pembro vs placebo, with HR 0.57 (43% reduction in the risk of recurrence). COMBI-AD study showed HR 0.47 (57% reduction in the risk of recurrence). The caveat here is that the immunotherapy studies had more higher-risk stage ...